Special Issue "Plant-Derived Functional Foods, Nutraceuticals, and Cosmeceuticals: From Basic to Applied Science"

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Chemical and Molecular Sciences".

Deadline for manuscript submissions: 31 October 2022 | Viewed by 6988

Special Issue Editor

Dr. Hari Prasad Devkota
E-Mail Website
Guest Editor
Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 860-8555, Japan
Interests: bioactive natural products; phytochemistry; inflammation; flavonoids; functional foods
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Medicinal plants play an important role in human healthcare as an integral part of traditional medicine systems and one of the main sources for the discovery and development for modern drugs. Plant extracts and their phytochemicals have also received increased attention in recent years as functional foods, food supplements, nutraceuticals, and cosmeceuticals. As the number of people with lifestyle-related diseases including diabetes, hypertension, hyperlipidemia, and associated complications is increasing worldwide, various plant-derived functional foods, food supplements, and nutraceuticals are marked as potential agents in the prevention and management of these complications. However, many such products do not have strong scientific evidence for their claimed activities. There is a growing need for detailed research related to the identification of new sources, characterization of active compounds, elucidation of mechanisms of action using in vitro, in vivo, and clinical studies, and product formulation.

This Special Issue of the journal Applied Sciences, “Plant-Derived Functional Foods, Nutraceuticals, and Cosmeceuticals: From Basic to Applied Science”, aims to cover recent advances in the discovery, chemical and pharmacological aspects, and formulation development of functional foods, nutraceuticals, and cosmeceuticals from basic and applied science perspectives. Original articles, communications, and reviews related to these topics are welcome for submission.

Dr. Hari Prasad Devkota
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • functional foods
  • nutraceuticals
  • food supplements
  • phytochemicals
  • cosmeceuticals
  • metabolic diseases

Related Special Issue

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
Identification of Common Liver Metabolites of the Natural Bioactive Compound Erinacine A, Purified from Hericium erinaceus Mycelium
Appl. Sci. 2022, 12(3), 1201; https://doi.org/10.3390/app12031201 - 24 Jan 2022
Viewed by 948
Abstract
Metabolite identification, in the early stage, for compound discovery is necessary to assess the knowledge for the pharmaceutical improvement of drug safety and efficacy. Even if the drug has been released into the market, identification and continuous evaluation of the metabolites are required [...] Read more.
Metabolite identification, in the early stage, for compound discovery is necessary to assess the knowledge for the pharmaceutical improvement of drug safety and efficacy. Even if the drug has been released into the market, identification and continuous evaluation of the metabolites are required to avoid the risk of post-marketing withdrawal. Hericium erinaceus (HE), a medicinal mushroom, has broadly documented nutraceutical benefits, including anti-oxidant, anti-tumor, anti-aging, hypolipidemic, and gastric mucosal protection effects. Recently, erinacine A has been reported as the main natural bioactive compound in the mycelium of HE for functional food development. In neurological studies, the consumption of enrinacine A enriched HE mycelium demonstrates its significant nutraceutical effects in Alzheimer’s disease, Parkinson’s disease, and ischemic stroke. For the first time, we explored the metabolic process of erinacine A molecule and identified its metabolites from the rat and human liver S9 fraction. Using a liquid chromatography/triple quadrupole mass spectrometer for quantitative analysis, we observed that 75.44% of erinacine A was metabolized within 60 min in rat, and 32.34% of erinacine A was metabolized within 120 min in human S9. Using an ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) to identify the metabolites of erinacine A, five common metabolites were identified, and their possible structures were evaluated. Understanding the metabolic process of erinacine A and establishing its metabolite profile database will help promote the nutraceutical application and discovery of related biomarkers in the future. Full article
Show Figures

Figure 1

Article
Evaluation of Anti-Obesity Activity of an Herbal Formulation (F2) in DIO Mice Model and Validation of UPLC-DAD Method for Quality Control
Appl. Sci. 2021, 11(16), 7404; https://doi.org/10.3390/app11167404 - 12 Aug 2021
Cited by 1 | Viewed by 1161
Abstract
Obesity is considered a chronic metabolic disorder that can be associated with multiple medical complications. Currently, there is no or limited curative therapy for obesity. This study focused on the assessment of anti-obesity activity and UPLC standardization of a polyherbal formulation (F2). An [...] Read more.
Obesity is considered a chronic metabolic disorder that can be associated with multiple medical complications. Currently, there is no or limited curative therapy for obesity. This study focused on the assessment of anti-obesity activity and UPLC standardization of a polyherbal formulation (F2). An anti-obesity activity was investigated using the diet-induced obese (DIO) mice model, where obesity was developed in C57BL/6J mice by providing a high-fat diet (HFD) for five weeks without treating drugs. After the successful development of obesity, the obese mice were treated with F2 for seven weeks with continuing HFD feeding. The major obesity-related parameters such as body weight gain, food efficiency ratio, serum lipid profile, and white adipose tissue (WAT) mass were found to be significantly reduced in F2 treated obese mice. These results were supported by the down-regulation of specific adipogenic transcription factors (PPARγ, SREBP-1c, and ap2) in epididymal WAT. Histological evaluation of liver and WAT also revealed reduced fat deposition in the tissues by F2 compared to the HFD control group. The overall observations indicated that the F2 exhibited pronounced obesity-controlling activity through the inhibition of adipocyte differentiation and triglyceride accumulation in the tissues, and serum lipid depletion. In addition, F2 ameliorated obesity-induced insulin resistance. Furthermore, the UPLC-DAD method for quality control of F2 was validated and standardized using five reference compounds: astragalin, ellagic acid, fisetin, fustin, and sulfuretin. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

Review
Bioactive Compounds from Zingiber montanum and Their Pharmacological Activities with Focus on Zerumbone
Appl. Sci. 2021, 11(21), 10205; https://doi.org/10.3390/app112110205 - 31 Oct 2021
Cited by 2 | Viewed by 1350
Abstract
The genus Zingiber consists of about 85 species and many of these species are used as food, spices, and medicines. One of the species, Zingiber montanum (J. Koenig) Link ex A. Dietr. is native to Southeast Asia and has been extensively used as [...] Read more.
The genus Zingiber consists of about 85 species and many of these species are used as food, spices, and medicines. One of the species, Zingiber montanum (J. Koenig) Link ex A. Dietr. is native to Southeast Asia and has been extensively used as traditional medicines and food. The aim of this review was to collect and critically analyze the scientific information about the bioactive compounds and pharmacological activities of Z. montanum with focus on one of the main components, zerumbone (ZER). Various studies have reported the analysis of volatile constituents of the essential oils from Z. montanum. Similarly, many phenylbutanoids, flavonoids and terpenes were also isolated from rhizomes. These essential oils, extracts and compounds showed potent antimicrobial, anti-inflammatory and antioxidant activities among others. Zerumbone has been studied widely for its anticancer, anti-inflammatory, and other pharmacological activities. Future studies should focus on the exploration of various pharmacological activities of other compounds including phenylbutanoids and flavonoids. Bioassay guided isolation may result in the separation of other active components from the extracts. Z. montanum could be a promising source for the development of pharmaceutical products and functional foods. Full article
Show Figures

Figure 1

Review
Actions and Therapeutic Potential of Madecassoside and Other Major Constituents of Centella asiatica: A Review
Appl. Sci. 2021, 11(18), 8475; https://doi.org/10.3390/app11188475 - 13 Sep 2021
Cited by 4 | Viewed by 962
Abstract
Centella asiatica is a popular herb well-known for its wide range of therapeutic effects and its use as a folk medicine for many years. Its therapeutic properties have been well correlated with the presence of asiaticoside, madecassoside, asiatic and madecassic acids, the pentacyclic [...] Read more.
Centella asiatica is a popular herb well-known for its wide range of therapeutic effects and its use as a folk medicine for many years. Its therapeutic properties have been well correlated with the presence of asiaticoside, madecassoside, asiatic and madecassic acids, the pentacyclic triterpenes. The herb has been extensively known to treat skin conditions; nevertheless, several pre-clinical and clinical studies have scientifically demonstrated its effectiveness in other disorders. Among the active constituents that have been identified in Centella asiatica, madecassoside has been the subject of only a relatively small number of scientific reports. Therefore, this review, while including other major constituents of this plant, focuses on the therapeutic potential, pharmacokinetics and toxicity of madecassoside. Full article
Show Figures

Figure 1

Review
Protective Effects of Tocotrienols in Cerebral and Myocardial Ischemia-Reperfusion Injury: A Systematic Review
Appl. Sci. 2021, 11(17), 7994; https://doi.org/10.3390/app11177994 - 29 Aug 2021
Cited by 1 | Viewed by 894
Abstract
Although the current treatments for stroke and myocardial infarction contribute to an improvement in mortality rates, the consequences of reperfusion therapy have remained a challenge. Tocotrienols have been shown to exert beneficial effects on the brain and heart. This review aimed to determine [...] Read more.
Although the current treatments for stroke and myocardial infarction contribute to an improvement in mortality rates, the consequences of reperfusion therapy have remained a challenge. Tocotrienols have been shown to exert beneficial effects on the brain and heart. This review aimed to determine the effects of tocotrienols in cerebral and myocardial ischemia-reperfusion (I/R) injury. We retrieved articles from Scopus, MEDLINE and PubMed from inception to June 2021, and included any studies using tocotrienols as a treatment for cerebral or myocardial I/R injury therapy. Observational studies and review articles were excluded, and the risk of bias was conducted using a specific tool for animal study (SYRCLE). The data were analyzed qualitatively. Twelve articles met the eligibility criteria. Tocotrienols significantly improved the structural, functional, and biochemical parameters in both cerebral and myocardial I/R injury models. In contrast, oxidative stress, inflammation, and apoptosis were markedly attenuated by tocotrienol treatment. Limitations to the analysis included marked differences in animal models, disease inductions, forms of tocotrienols, and an unclear risk of bias in certain types of bias. However, tocotrienols have the potential to serve as a supplement for reducing the impact of reperfusion injury. Full article
Show Figures

Figure 1

Back to TopTop